A phase I clinical trial using armored GPC3 CAR T cells for children with relapsed/refractory liver tumors.

TPS2647Background: CAR T therapies have been successful against hematologic malignancies, but have benefited only a handful of patients with solid cancers. Glypican 3 (GPC3) is an attractive immuno...